Clinical trials: Immune Responses
Meningococcal Disease
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
The purpose of this extension study is to evaluate the immunogenicity and safety of a booster dose of a MenABCWY vaccine, administered 24 months after completion of the primary vaccination series, in subjects who previously…
- Trial name
- NCT01992536
- Testing
- MenABCWY+OMV, MenABCWY+¼OMV
- Where
- 13 sites in United States, Poland
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Covid-19, SARS-CoV Infection
RT-PCR Database Analysis for COVID-19 Infections and Re-infection
The SARS-Cov2 pandemic remains associated with many concerns. One of the them is the real frequency of likely re-infection and subsequently the level of protection conferred by the acquired immunity following primary-infection.
- Trial name
- ReCOV (NCT04653844)
- Where
- France
- Volunteers
- 7,000,000 people
- Sponsor
- University Hospital, Montpellier
Hematologic Diseases
Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study
The main objective of this study is to investigate the humoral immune response to COVID-19 vaccines in haematological patients, by testing SARS-CoV-2 seroconversion
- Trial name
- Hema-C19-Vax (NCT05074706)
- Testing
- IgG antibodies to Sars-Cov-2, QuantiFERON SARS-CoV-2 test
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- University of Milano Bicocca
Primary Immune Deficiency Disorder
Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
This is a Phase III, multicenter, open-label study of RI-002 administered as an intravenous infusion of RI-002 (IGIV) every 21 or 28 days in approximately 60 subjects with Primary Immunodeficiency Diseases (PIDD).
- Trial name
- NCT01814800
- Testing
- RI-002
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- ADMA Biologics, Inc.
Infectious Gastroenteritis
Probiotics for Infectious Diarrhea in Children in South India
The overall goal of this study is to investigate whether the modulatory effects of probiotics, which are used as food supplements (Lactobacillus GG marketed as Culturelle or yoghurt) in the gastrointestinal tract promote…
- Trial name
- NCT01130792
- Testing
- Lactobacillus GG, Inulin
- Where
- India
- Volunteers
- 124 people
- Sponsor
- Christian Medical College, Vellore, India
Gut Microbiome, Healthy Adult Male
Effect of Antifungals on the Intestinal Microbiome - a Randomized, Controlled, Proof-of-concept Trial
The goal of this clinical trial is to learn how the antifungal drug fluconazole affects the gut microbiome and immune system in healthy volunteers.
- Conditions
- Gut Microbiome, Healthy Adult Male, Antifungal Therapy
- Trial name
- FAME (NCT07295314)
- Testing
- Fluconazole 200mg tab
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Multiple Sclerosis, Pregnancy
Exercise and Pregnancy in People With Multiple Sclerosis
The purpose of this study is to examine acute physiological responses to exercise and activity patterns of people with multiple sclerosis (MS) during pregnancy and postpartum.
- Trial name
- NCT05313204
- Testing
- Moderate-intensity cardiovascular exercise
- Where
- Canada
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Non-Hodgkin's Lymphoma
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.
- Trial name
- NCT00090038
- Testing
- rituximab
- Where
- 45 sites in United States, Austria and 9 more
- Volunteers
- 168 people
- Sponsor
- Biogen
Inflammatory Disorder of Immune System, Sepsis
Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status
ICU patients always experience all kinds of pain, discomfort and sleep disturbance,especially the sepsis patients. Appropriate sedation and analgesia is must,the newest sepsis guideline strongly recommend that mechanically…
- Trial name
- NCT02135055
- Testing
- blood sample collection, Midazolam, Morphine
- Volunteers
- 80 people
- Sponsor
- Xiangya Hospital of Central South University
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Dietary Intervention
Probiotic, Prebiotic and Synbiotic Effect on Immunity
The aim of the study is to investigate the effect of dietary supplements such as probiotic, prebiotic and synbiotic on the immune response to influenza vaccination and faecal microbiota in adult healthy volunteers.
- Trial name
- NCT01084434
- Testing
- probiotic, prebiotic, Synbiotic
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Reading
Severe Asthma
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies.
- Trial name
- PREDICTUMAB (NCT03476109)
- Testing
- Randomisation to omalizumab, Randomisation to mepolizumab
- Where
- 13 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Antibody Persistance After Booster Dose of Men C Vaccine
Understanding Immunity Persistence After Adolescent MenC Vaccination
The main purpose of this study is to evaluate the duration of immunity after a booster dose of a MenC-CRM vaccine given to adolescents between 13 and 15 years of age.
- Trial name
- NCT01459432
- Testing
- Venepuncture and blood sample collection.
- Where
- United Kingdom
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Inflammation, Psychosocial Functioning
Mindfulness Meditation Neuroimaging Study for Undergraduates
This study is designed to test the effectiveness of mindfulness meditation intervention classes on psychosocial health outcomes.
- Conditions
- Inflammation, Psychosocial Functioning, Depression, Anxiety
- Trial name
- NCT05304052
- Testing
- Mindfulness Meditation classes
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Lymphoma
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
This study will evaluate the efficacy and safety of MabThera plus high dose methotrexate plus high dose cytarabine in patients with central nervous system non-Hodgkin's lymphoma.
- Trial name
- NCT00517699
- Testing
- rituximab [MabThera/Rituxan], Methotrexate, Cytarabine
- Where
- 2 sites in Canada
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Prevention of Meningococcal Infection
Persistence of Immune Response After Vaccination With MCC
Persistence of Immune response after vaccination with MCC
- Trial name
- NCT00310687
- Testing
- BLOOD DRAW
- Where
- United Kingdom
- Volunteers
- 1,244 people, healthy volunteers welcome
- Sponsor
- Novartis
High Blood Pressure, Salt; Excess
Salt-Sensitivity and Immunity Cell Activation
Salt-sensitive hypertension affects nearly 50% of the hypertensive and 25% of the normotensive population, and strong evidence indicates that reducing salt intake decreases blood pressure and cardiovascular events.
- Conditions
- High Blood Pressure, Salt; Excess, Inflammation
- Trial name
- NCT03753204
- Testing
- Furosemide 40 mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Narcolepsy 1, Kleine-Levin Syndrome
Microglial Activation in Narcolepsy Type 1 and Kleine-Levin Syndrome: Positron Emission Tomography (PET) Study in [18F] DPA-714
Type 1 narcolepsy (NT1) is a chronic sleep disorder caused by the selective and irreversible loss of neurons from the hypothalamus, which synthesizes a neurotransmitter: hypocretin (Hcrt) / orexin.
- Trial name
- NARCOGLIE (NCT03754348)
- Testing
- PET scan with tracer injection [18F] DPA-714
- Where
- France
- Volunteers
- 78 people
- Sponsor
- University Hospital, Montpellier
Hepatocellular Carcinoma, Immune Response
Immunological Response After Ablative Therapy in the Liver
Local ablative treatment of Hepatocellular Carcinoma is performed primary on patients not eligible for liver transplant or liver resection.
- Trial name
- IRAL (NCT03040453)
- Testing
- Microwave ablation, Irreversible electroporation
- Where
- Sweden
- Sponsor
- Karolinska Institutet
Awaiting Organ Transplant, Infection in Solid Organ Transplant Recipients
Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common infection with 60-90% of all adults worldwide having evidence of having the infection at sometime in their life.
- Trial name
- ViracorCMI (NCT01558037)
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Michael Ison